Highlight
1. The ACCORD randomized clinical trial showed that camrelizumab combined with capecitabine and radiotherapy significantly improved overall and recurrence-free survival in patients with resectable extrahepatic cholangiocarcinoma and gallbladder cancer.
2. The combination therapy demonstrated a well-tolerable safety profile with no treatment-related deaths and high completion rates.
3. This study fills the gap of effective adjuvant options specific to extrahepatic cholangiocarcinoma and gallbladder cancer, distinct from intrahepatic cholangiocarcinoma.
4. Further investigation comparing this regimen to active chemotherapy or chemoradiotherapy is warranted.
